Dosed first patients in a key wound care trial and expects interim results in 2H 2026. R&D expenses declined year-over-year, net loss was $4.1M, and cash totaled $3.5M. Raised $12M in new financing and expanded patent portfolio.Original document: FibroBiologics, Inc. [FBLG] SEC 8-K Current Report —…
Dosed first patients in a key wound care trial and expects interim results in 2H 2026. R&D expenses declined year-over-year, net loss was $4.1M, and cash totaled $3.5M. Raised $12M in new financing and expanded patent portfolio.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
